Rocket One Inc. Common Stock (NASDAQ:RKTO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings cut Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Rocket One Inc. Common Stock Stock Performance

Rocket One Inc. Common Stock stock opened at $0.79 on Friday. The stock has a market cap of $17.64 million, a P/E ratio of -0.99 and a beta of 0.96. Rocket One Inc. Common Stock has a fifty-two week low of $0.49 and a fifty-two week high of $2.45. The firm’s fifty day moving average price is $1.02 and its 200-day moving average price is $0.92.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03).

Hedge Funds Weigh In On Rocket One Inc. Common Stock

Several institutional investors have recently modified their holdings of the company. Lido Advisors LLC bought a new stake in Rocket One Inc. Common Stock in the 3rd quarter worth approximately $32,000. Kestra Private Wealth Services LLC purchased a new stake in Rocket One Inc. Common Stock in the third quarter worth approximately $51,000. Virtu Financial LLC bought a new position in Rocket One Inc. Common Stock during the third quarter valued at approximately $184,000. Geode Capital Management LLC grew its position in Rocket One Inc. Common Stock by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Rocket One Inc. Common Stock during the third quarter worth approximately $232,000. 7.08% of the stock is currently owned by institutional investors.

Rocket One Inc. Common Stock Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.